| Literature DB >> 2839778 |
Abstract
Lithium (Li) at a concentration, which exerts prophylactic effects in affective disorders is known to alter noradrenaline turnover and the beta-adrenoceptor-dependent cAMP accumulation. In the present study the action of chronic Li administration (at least 5 weeks) on agonist and antagonist binding to adrenoceptors and on the regulation of adrenoceptors was investigated in rat cerebral cortex. Li treatment caused a small but significant decrease in the number of beta-adrenoceptor binding sites by 10% (3H-dihydroalprenolol binding) leaving the number of alpha 1- and alpha 2-adrenoceptor binding sites (3H-prazosin and 3H-rauwolscine, respectively) unchanged. The affinity of the radioligands as well as the affinity of agonists to these binding sites were not altered. The up-regulation of beta-adrenoceptor binding sites produced by repeated reserpine injections was inhibited by 32% in rats treated concomitantly with Li, although the noradrenaline depleting effect of reserpine was not impaired. In contrast, Li treatment had no effect on the up-regulation of beta-adrenoceptor binding induced by 6-OH-dopamine, nor did it alter the beta-adrenoceptor down-regulation following chronic administration of desipramine. The up-regulation of alpha 1-adrenoceptor binding sites caused by reserpine or 6-OH-dopamine also remained unaffected by Li. It is concluded that chronic Li has limited effects on cortical adrenoceptors and their regulation. The inhibition of beta-adrenoceptor up-regulation caused by reserpine may reflect an action of Li on non-adrenergic systems rather than a general "stabilizing" effect on adrenoceptors proposed previously.Entities:
Mesh:
Substances:
Year: 1988 PMID: 2839778 DOI: 10.1007/BF00168837
Source DB: PubMed Journal: Naunyn Schmiedebergs Arch Pharmacol ISSN: 0028-1298 Impact factor: 3.000